Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc. 1 DNA Way, South San Francisco, CA, USA.
Pharm Dev Technol. 2013 Jul-Aug;18(4):877-82. doi: 10.3109/10837450.2012.696265. Epub 2012 Jun 12.
An anomalous peak was observed in the HPLC/UV analysis of a developmental drug product. High resolution LC/MS revealed that the mass of this degradant was 12 Da greater than the drug substance, corresponding to a net gain of a single carbon atom. The degradant was reproduced by incubating the drug substance with formaldehyde, followed by isolation using normal phase chromatography and structure elucidation by NMR. It was determined to be an analytical artifact caused by the nucleophilic reaction of the drug substance with trace levels of formaldehyde in the methanol diluent. Typical formaldehyde levels in various grades of methanol were determined, leading to the adoption of spectrophotometric purity solvent to mitigate the recurrence of this artifact. This work demonstrates that even ppm levels of impurities in solvents can cause significant degradation of drug product and the HPLC grade solvents are not always suitable for HPLC analysis in drug product development.
在对一种开发中的药物产品进行 HPLC/UV 分析时,观察到一个异常峰。高分辨率 LC/MS 显示,该降解产物的质量比药物母体大 12 Da,对应于单个碳原子的净增加。通过使药物母体与甲醛孵育,然后使用正相色谱法分离,并通过 NMR 进行结构阐明,可重现该降解产物。确定它是由药物母体与甲醇稀释剂中痕量甲醛的亲核反应引起的分析性假象。测定了各种级别的甲醇中的典型甲醛水平,导致采用分光光度纯度溶剂来减轻该假象的重现。这项工作表明,即使溶剂中的杂质 ppm 水平也会导致药物产品的显著降解,并且 HPLC 级溶剂并不总是适合药物产品开发中的 HPLC 分析。